Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sutro Biopharma (STRO) Return on Sales (2017 - 2025)

Sutro Biopharma's Return on Sales history spans 9 years, with the latest figure at 5.08% for Q3 2025.

  • For Q3 2025, Return on Sales rose 65.0% year-over-year to 5.08%; the TTM value through Sep 2025 reached 1.92%, down 111.0%, while the annual FY2024 figure was 3.67%, 297.0% down from the prior year.
  • Return on Sales for Q3 2025 was 5.08% at Sutro Biopharma, down from 0.15% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.27% in Q4 2023 and bottomed at 12.25% in Q1 2025.
  • The 5-year median for Return on Sales is 3.7% (2023), against an average of 3.54%.
  • The largest annual shift saw Return on Sales soared 428bps in 2023 before it tumbled -777bps in 2025.
  • A 5-year view of Return on Sales shows it stood at 3.58% in 2021, then dropped by -12bps to 4.01% in 2022, then soared by 107bps to 0.27% in 2023, then crashed by -1891bps to 4.89% in 2024, then fell by -4bps to 5.08% in 2025.
  • Per Business Quant, the three most recent readings for STRO's Return on Sales are 5.08% (Q3 2025), 0.15% (Q2 2025), and 12.25% (Q1 2025).